More Industry News

  • Aestus partners with nonprofit biotech institute to test ALS drugs

    The ALS Therapy Institute has agreed to collaborate with New Jersey-based Aestus Therapeutics to conduct studies on small-molecule drugs that could delay or halt the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease. The institute will be in charge of testing the compounds identified by Aestus using a preclinical model of the condition.

    Read more

  • Green alga holds promise for pharmaceutical production

    Scientists at the University of California, San Diego, found that the green alga Chlamydomonas reinhardtii is capable of producing therapeutic proteins at a level ample for commercial production and with qualities comparable to those produced by bacterial and mammalian cell systems. They said algae could serve as an easy and cost-effective approach for drug manufacturing.

    Read more

  • Hikma CEO's acquisition strategy includes maximizing market value

    Hikma Pharmaceuticals CEO Said Darwazah said the Jordanian company will continue to turn down takeover offers until its market value reaches $7.7 billion. "We're constantly in talks," Darwazah said. "We want to enter markets we're not in, like Morocco. We also want to enter markets we have yet to gain 5% market share in, like Tunisia and Egypt. Our goal is to get 5% market share in every market we're in."

    Read more

  • Large study aims to advance personalized breast cancer drugs

    The University of Minnesota and the Mayo Clinic are taking part in a study to identify which drug candidates for breast cancer would best benefit different groups of patients. The research, conducted at 17 centers nationwide, might reduce by 10 years the time it takes to get a new drug approved, said Dr. Tufia Haddad, head of the research at the university.

    Read more

  • Roche plans to stay away from "mega-mergers," CEO says

    Roche Holding will focus on research deals in programs such as Alzheimer's disease and diabetes to "constantly rejuvenate" its pipeline, CEO Severin Schwan said. "We would only look at smaller and medium-size acquisitions," Schwan said. "We would not go for big mega-mergers like you see happening in the industry. We would go where the science takes us."

    Read more

  • Source: Pfizer might try to buy Stada if Ratiopharm bid falls through

    Pfizer might bid to acquire Stada, a generics company in Germany, if Ratiopharm rejects its final takeover offer, a source said. Some analysts said Pfizer might gain more from Stada because of its business in emerging markets.

    Read more

Powered by SmartBrief